Briviact
Drug
UCB, Inc.
Total Payments
$14.1M
Transactions
161,812
Doctors
17,200
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 27,465 | 6,643 |
| 2023 | $1.3M | 28,168 | 6,701 |
| 2022 | $1.6M | 24,381 | 6,292 |
| 2021 | $1.2M | 22,495 | 5,413 |
| 2020 | $1.4M | 10,252 | 3,124 |
| 2019 | $2.2M | 16,406 | 4,135 |
| 2018 | $2.8M | 12,745 | 3,191 |
| 2017 | $2.3M | 19,900 | 4,334 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.7M | 464 | 33.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.5M | 3,201 | 32.2% |
| Food and Beverage | $3.3M | 154,242 | 23.3% |
| Consulting Fee | $1.1M | 528 | 7.5% |
| Travel and Lodging | $476,045 | 3,311 | 3.4% |
| Space rental or facility fees (teaching hospital only) | $37,675 | 24 | 0.3% |
| Education | $1,658 | 42 | 0.0% |
Payments by Type
General
$9.4M
161,348 transactions
Research
$4.7M
464 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MULTICENTER 1 YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM. | UCB, Inc. | $1.2M | 0 |
| OPEN-LABEL, SINGLE-ARM, MULTICENTER, LONG-TERM STUDY TO EVALUATE SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN PEDIATRIC SUBJECTS WITH EPILEPSY PHASE 3 | UCB SA | $660,138 | 0 |
| Does Brivaracetam (BRV) have a faster onset time and greater effect than levetiracetam (LEV) in epilepsy patients? A prospective, randomized, crossover, double-blind, controlled intravenous study using the evoked photoparoxysmal EG response (PR) as a pharmacodynamics efficacy endpoint. | UCB, Inc. | $535,302 | 0 |
| AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY | UCB Biosciences Inc. | $424,993 | 0 |
| MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM | UCB SA | $382,653 | 0 |
| A RANDOMIZED, DOSE-FINDING AND CONFIRMATORY, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP MULTICENTER STUDY WITH A 2-STAGE ADAPTIVE DESIGN AND RANDOMIZED WITHDRAWAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BRIVARACETAM AS MO | UCB SA | $313,658 | 0 |
| A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS >=1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY | UCB SA | $165,501 | 0 |
| A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BRIVARACETAM IN STUDY PARTICIPANTS 2 TO 26 YEARS OF AGE WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY | UCB SA | $152,867 | 0 |
| A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study with a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety and Tolerability of brivaracetam as Monotherapy in Patients 2 to 25 Years of Age with Childhood Absence Epilepsy or Juvenile Absence Epilepsy (Phase 2/3) | UCB SA | $138,803 | 0 |
| Open-label, single-arm, multicenter study to evaluate Long-TERM safety and Tolerability of brivaracetam used as adjunctive treatment in pediatric study participants with epilepsy. | UCB SA | $117,017 | 0 |
| A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH EPILEPSY | UCB SA | $105,516 | 0 |
| Support as Sponsor of North American AED (Antiepileptic Drug) Pregnancy Registry for the year 2017 reports Brivaracetam, Lacosamide, Levetiracetam | UCB Biosciences Inc. | $85,000 | 0 |
| An open-label, multinational, multicenter, follow-up study to evaluate the long-term safety and efficacy of brivaracetam, used at a flexible dose up to a maximum of 200 mg/day, in subjects aged 16 years or older suffering from epilepsy. | UCB Biosciences Inc. | $71,401 | 0 |
| Brivaracetam in the Treatment of Refractory Status Epilepticus | UCB SA | $65,437 | 0 |
| A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS ?1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY | UCB SA | $31,350 | 0 |
| AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY PHASE 3b | UCB SA | $29,862 | 0 |
| Does Brivaracetam BRV have a faster onset time and greater effect than levetiracetam LEV in epilepsy patients A prospective, randomized, crossover, double-blind, controlled intravenous study using the evoked photoparoxysmal EG response PR as a pharmacodynamics efficacy endpoint. | UCB, Inc. | $27,910 | 0 |
| OPEN-LABEL, SINGLE-ARM, MULTICENTER, LONG-TERM STU | UCB SA | $24,953 | 0 |
| A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVA | UCB SA | $23,169 | 0 |
| An open-label, multicenter, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subjects aged 16 years or older suffering from epilepsy. | UCB Biosciences Inc. | $16,932 | 0 |
Top Doctors Receiving Payments for Briviact
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| John Messenheimer | — | Chapel Hill, NC | $4.7M | 481 |
| , MD | Epilepsy | Grand Rapids, MI | $408,329 | 645 |
| , MD | Neurology | Bethesda, MD | $371,733 | 537 |
| , MD MS | Critical Care Medicine | Cincinnati, OH | $359,253 | 586 |
| , M.D | Neurology | East Lansing, MI | $296,340 | 439 |
| , M.D | Neurology | San Francisco, CA | $281,182 | 459 |
| , MD | Neurology | Cincinnati, OH | $208,599 | 481 |
| , M.D | Neurology | Phoenix, AZ | $199,802 | 405 |
| , M.D | Neurology | Fort Wayne, IN | $186,130 | 382 |
| , MD | Neurology | Lexington, KY | $141,337 | 324 |
| , MD, PHD, FAAN | Clinical Neurophysiology | Boise, ID | $133,800 | 220 |
| , M.D | Clinical Neurophysiology | St Petersburg, FL | $114,674 | 186 |
| , MD | Neurology | Billings, MT | $91,872 | 181 |
| , M.D | Specialist | Baltimore, MD | $90,448 | 153 |
| Jerzy Szaflarski | Neurology | Cincinnati, OH | $81,523 | 29 |
| , M.D., PH.D | Neurology | Baltimore, MD | $81,411 | 204 |
| , M.D | Neurology | Tulsa, OK | $77,888 | 131 |
| , MD | Clinical Neurophysiology | Chicago, IL | $75,753 | 100 |
| , MD | Epilepsy | New Orleans, LA | $71,758 | 123 |
| , MD | Epilepsy | Cleveland, OH | $70,335 | 122 |
| , MD | Clinical Neurophysiology | Los Angeles, CA | $69,163 | 123 |
| , MD | Clinical Neurophysiology | Orange, CA | $65,502 | 121 |
| , DO | Neurology | Garden City, MI | $63,925 | 97 |
| , MD | Neurology | Pittsburgh, PA | $60,821 | 64 |
| , MD | Sleep Medicine | Sarasota, FL | $60,415 | 192 |
Ad
Manufacturing Companies
- UCB, Inc. $11.0M
- UCB SA $2.4M
- UCB Biosciences Inc. $643,243
- UCB GmBH $6,970
Product Information
- Type Drug
- Total Payments $14.1M
- Total Doctors 17,200
- Transactions 161,812
About Briviact
Briviact is a drug associated with $14.1M in payments to 17,200 healthcare providers, recorded across 161,812 transactions in the CMS Open Payments database. The primary manufacturer is UCB, Inc..
Payment data is available from 2017 to 2024. In 2024, $1.3M was paid across 27,465 transactions to 6,643 doctors.
The most common payment nature for Briviact is "Unspecified" ($4.7M, 33.3% of total).
Briviact is associated with 20 research studies, including "MULTICENTER 1 YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM." ($1.2M).